Encephalomyelitis

Summary

Encephalomyelitis (MONDO:0005156) is a disease (an umbrella term covering 7 Mondo subtypes) and 4 clinical trials. Top therapeutic interventions include azathioprine. A subtype of central nervous system disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Umbrella term: 7 Mondo subtypes
• Clinical trials: 4

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	encephalomyelitis
Mondo ID	MONDO:0005156
EFO	EFO:0001423
MeSH	D004679
DOID	DOID:640
NCIT	C34580
SNOMED CT	62950007
UMLS	C0014070
MedGen	8603
Is cancer (heuristic)	no

Also known as: central nervous system inflammation · encephalitis and/or myelitis · inflammation of central nervous system

Disease family

This is a subtype of central nervous system disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › encephalomyelitis

Related subtypes (18): autoimmune disorder of central nervous system, autonomic nervous system disorder, optic nerve disorder, spinal cord disorder, high pressure neurological syndrome, central nervous system vasculitis, neurodegenerative disease, brain disorder, central nervous system neoplasm, palsy, trigeminal neuralgia, infantile cerebral and cerebellar atrophy with postnatal progressive microcephaly, sporadic fetal brain disruption sequence, congenital narrowing of cervical spinal canal, central nervous system infectious disorder, cerebrospinal fluid leak, SPAST-related motor disorder, tinnitus

Subtypes (7): myelitis, cerebritis, optic neuritis, Venezuelan equine encephalitis, encephalitis, meningitis, hypophysitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 2 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Azathioprine	Phase 3 (in late-stage trials)
Rintatolimod	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Tacrolimus Anhydrous.

Clinical trials & evidence

Clinical trials

Clinical trials: 4.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	2
PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05349006	PHASE3	RECRUITING	Azathioprine in MOGAD
NCT03776994	PHASE1	UNKNOWN	Venezuelan Equine Encephalitis Monovalent Virus-Like Particle Vaccine
NCT07540182	Not specified	NOT_YET_RECRUITING	The Aim of the Present Study is to Determine Outcome Predictors in Children Who Were Diagnosed as Acute Disseminated Encephalomyelitis (ADEM).
NCT07551999	Not specified	RECRUITING	A Study Of Remote Voice Analysis Tool For Diagnosing And Monitoring ME/CFS

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
AZATHIOPRINE	4	1